Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 1;5(7):662-664.
doi: 10.1002/bco2.406. eCollection 2024 Jul.

Value of a confirmatory re-biopsy as part of a modern risk stratified cancer surveillance programme for early prostate cancer

Harry Gabb  1 , Vincent J Gnanapragasam  1   2   3
Affiliations

Value of a confirmatory re-biopsy as part of a modern risk stratified cancer surveillance programme for early prostate cancer

Harry Gabb et al. BJUI Compass. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. eCollection 2024 Dec. BJUI Compass. 2024. PMID: 39744071 Free PMC article.
No abstract available

Keywords: Cambridge Prognostic Groups; active surveillance; confirmatory biopsy; prostate cancer; risk‐based follow‐up; stratified cancer surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. King AC, Livermore A, Laurila TA, Huang W, Jarrard DF. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favourable risk prostate cancer. Urol Oncol. 2013;31(6):739–743. 10.1016/j.urolonc.2011.06.011 - DOI - PMC - PubMed
    1. Osses DF, Drost FH, Verbeek JFM, Luiting HB, van Leenders GJLH, Bangma CH, et al. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary? BJU Int. 2020;126(1):124–132. 10.1111/bju.15065 - DOI - PMC - PubMed
    1. Thurtle D, Barrett T, Thankappan‐Nair V, Koo B, Warren A, Kastner C, et al. Progression and treatment rates using an active surveillance protocol incorporating image‐guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable‐risk prostate cancer. BJU Int. 2018;122(1):59–65. 10.1111/bju.14166 - DOI - PubMed
    1. Gnanapragasam VJ, Barrett T, Thankapannair V, Thurtle D, Rubio‐Briones J, Domínguez‐Escrig J, et al. Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow‐up in active surveillance for prostate cancer. BJU Int. 2019;124(5):758–767. 10.1111/bju.14800 - DOI - PubMed
    1. Thankapannair V, Keates A, Barrett T, Gnanapragasam VJ. Prospective implementation and early outcomes of a risk‐stratified prostate cancer active surveillance follow‐up protocol. Eur Urol Open Sci. 2023;49:15–22. 10.1016/j.euros.2022.12.013 - DOI - PMC - PubMed

LinkOut - more resources